Cancer Network spoke with Jennie Williams, PhD, and Jenny Paredes, a PhD student, about how tumor biology impacts chemotherapy response in African American vs Caucasian patients.
Cancer Network spoke with Jennie Williams, PhD, and Jenny Paredes, a PhD student, about how tumor biology impacts chemotherapy response in African American vs Caucasian patients.
Frontline Chemo-Free Regimen Supported in HR+/HER2+ Breast Cancer Therapy
January 1st 2024Combining anastrozole with palbociclib, trastuzumab, and pertuzumab as a frontline therapy for hormone receptor–positive, HER2-positive breast cancer may avoid some of the toxicities associated with chemotherapy, says Amy Tiersten, MD.